LL-37

Price and cost-per-mg comparison

LL-37 is the mature human cathelicidin antimicrobial peptide, a 37-amino-acid cationic peptide generated by proteolytic cleavage of the hCAP18 precursor protein, constitutively expressed in neutrophil granules and inducibly expressed in keratinocytes and epithelial cells of the skin, lung, and gastrointestinal tract as a component of innate antimicrobial defense. LL-37 disrupts bacterial and fungal membranes through electrostatic interaction with anionic lipopolysaccharide and membrane phospholipids, and also modulates inflammatory responses through formyl peptide receptor 2 (FPR2/ALX) activation, promotes wound healing via EGFR transactivation, and contributes to neutrophil extracellular trap formation and antiviral defense. Human studies have documented LL-37 expression in the context of severe soft tissue infections caused by Streptococcus pyogenes, and biochemical characterization of the hCAP18/LL-37 prosequence has identified antimicrobial and protease-inhibitory functions relevant to human skin defense biology. LL-37 is a research compound with no FDA approval for any indication; exogenous synthetic LL-37 administration is investigational with no completed human clinical trials establishing safety or efficacy for wound healing, antimicrobial, or immunomodulatory applications. LL-37 dosage and administration: No human clinical trial has established a dosage protocol for exogenous LL-37. Preclinical and in vitro studies have used LL-37 at concentrations ranging from 1–50 µg/mL in cellular models. Animal models have employed weight-based dosing via subcutaneous or intravenous delivery. Topical formulations for wound healing and antimicrobial applications have been investigated at varying concentrations, with interest in hydrogel delivery systems for sustained local release. LL-37 is rapidly degraded by host proteases in vivo, which limits systemic bioavailability following subcutaneous injection; this degradation susceptibility has driven research into protease-resistant LL-37 analogues and encapsulated formulations. LL-37 is a research compound with no approved human dosing guidelines for any indication.

43 listings · 38 vendors · updated 26 Oct 2026 · how prices are computed · educational only, not medical advice